Fósforo-32 e itrio-90 como opciones en el tratamiento del dolor óseo metastásico
Resumen
Palabras clave
Referencias
MERCADANTE S. Malignant bone pain: pathophysiology and treatment. Pain. 1997; 69(1-2): 1-18.
MUNDY GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2002; 2(8): 584-593.
International Atomic Energy Agency. Criteria for palliation of bone metastases-clinical applications. IAEA-TECDOC 1549. Vienna: IAEA, 2007. ISBN 92-0-104507-7.
SCHULMAN KL, KOHLES J. Economic burden of metastatic bone disease in the US. Cancer. 2010; 109(11): 2334-2342.
LI S, PENG Y, WEINHANDL ED, et. al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012; 4: 87-93.
YU HH, TSAI YY, HOFFE SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control. 2012; 19(2): 84-91.
ZHU XC, ZHANG JL, GE CT, et. al. Advances in cancer pain from bone metastasis. Drug Des Devel Ther. 2015; 18(9): 4239-4245.
PANDIT-TASKAR N, BATRAKI M, DIVGI CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J. Nucl. Med. 2004; 45(8): 1358-1365.
IBRAHIM T, MERCATALI L, AMADORI D. A new emergency in oncology: bone metastases in breast cancer patients (review). Oncol Lett. 2013; 6(2): 306-310.
TAYLOR DW. Economic and clinical net benefitsfrom the use of samarium Sm-153 lexidronam injection in the treatment of bone metastases. Intern J Tumor Therapy. 2013; 2(1): 10-17.
KIROU-MAURO AM, HIRD A, WONG J, et. al. Has pain manaagement of painful bone metastases with an emphasis on radionuclide therapy. J. Natl Med Assoc. 2007; 99(7): 785-794.
TOMBLYN M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metas-tases. Cancer Control. 2012; 19(2): 137-144.
SILBERSTEIN EB. Teletherapy and radiopharmaceutical therapy of painful bone metastasis. Semin. Nucl. Med. 2005; 35(2): 152-158.
PAUWELS EKJ, STOKKEL MP. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice. Q J Nucl. Med. 2001; 45(1): 18-26.
LEWINGTON VJ. Bone-Seeking radionuclides for therapy. J. Nucl. Med. 2005; 46(suppl. 1): 38S-47S.
GUPTA M, CHOUDHURY PS. Systemic radionuclide therapy for bone pain palliation in cancer patients. Cancer News. 2014, 8(2): 12-14. http://www.rgcirc.org/UserFiles/cancer-news-june-2014.pdf
KRISHNAMURTHY G, KRISHNAMURTHY S. Radionuclides for metastatic bone pain palliation: a need for rational revaluation in the new millennium. J. Nucl. Med. 2000; 41(4): 688-691.
SERAFINI AN. Therapy of Metastatic Bone Pain. J. Nucl. Med. 2001; 42(6): 895-906.
SILBERSTEIN EB, ELGAZZAR AH, KAPILIVSKY A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin. Nucl. Med. 1992; 22(1): 17-27.
SILBERSTEIN EB. The treatment of painful osseous metastases with 32P- labeled phosphates. Semin. Oncol. 1993; 20(3) suppl2: 10-21.
SILBERSTEIN EB. Advances in our understanding of the treatment of painful bone metastases. J. Nucl. Med. 2000; 41(4): 655-657.
BOUCHET LG, BOLCH WE, MURTY GS, et. al. Considerations of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J. Nucl. Med. 2000; 41(4): 682-687.
SRIVASTAVA SC. Treatment of bone and join pain with electron emitting radiopharmaceuticals. Indian J. Nucl. Med. 2004; 19(3): 89-97.
FETTICH J, PADHY A, NAIR N. Comparative clinical efficacy and safety of phosphorous-32 and Strontium-89 in the palliative treatment of metastatic bone pain: results of an IAEA coordinated research Project. World J. Nucl. Med. 2003; 2(3): 226-231.
KHAN AU, KHAN SU, IQBAl M, KHAN A, SHAHID S. Metastatic bone pain palliation with P-32 in combination with vitamin D, Our preliminary experience. http://www.iaea.org/inis/collection/NCL-CollectionStore/_Public/43/005/43005480.pdf
PORTILLA I, ALSINA S. de la C, OLIVA JP, et. al. P-32 en el tratamiento de las metástasis óseas por carcinoma prostático. Revista Cubana de Oncología. 2000; 16(1): 44-47.
GARCÍA E, ALBERTI A, CRUZ J, MORIN J. Radiofármacos en el tratamiento del dolor por metástasis óseas. Nucleus. 2012; (52): 50-53.
ALBERTI A, CRUZ A, MORIN J. Itrio 90 como radionúclido para terapia. Nucleus. 2012; (52): 62-67.
GODDU SM, BISHAYEE A, BOUCHET LG, et. al. Marrow toxiciy of 33P-versus 32P-Orthophosphate: implications for therapy of bone pain and bone metastases. J. Nucl. Med. 2000; 41 (5): 941-951.
MALJA S, SCHOMACKER K, MALJA E. Preparation of 90Y by the 90 Sr-90Y generator for medical purpose. J Radioanal Nucl Chemistry. 2000; 245(2): 403-406.
RÖSCH F, HERZOG H, PLAG C, et. al. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur. J. Nucl. Med. 1996; 23(8): 958-966.
BALOGH I, GALLER Z, LANDHERR L. Do we really have to be cautious of repeating the Y-90-EDTMP therapy for bone pain palliation? J. Nucl. Med. 2013; 54 (suppl 2): 1405.